Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly

Clinical Endocrinology

Volumn 53, Issue 5, 2000, Pages 577-586

  Chanson, P ^a   Boerlin, V ^a   Ajzenberg, C ^a   Bachelot, Y ^a   Benito, P ^a   Bringer, J ^a   Caron, P ^a   Charbonnel, B ^a   Cortet, C ^a   Delemer, B ^a   Escobar Jimenez, F ^a   Foubert, L ^a   Gaztambide, S ^a   Jockenhoevel, F ^a   Kuhn, J M ^a   Leclere, J ^a   Lorcy, Y ^a   Perlemuter, L ^a   Prestele, H ^a   Roger, P ^a   Rohmer, V ^a   Santen, R ^a   Sassolas, G ^a   Scherbaum, W A ^a   Schopohl, J ^a   Torres, E ^a   Varela, C ^a   Villamil, F ^a   Webb, S M ^a   more..

^a BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE;

ACROMEGALY; AGED; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT INDICATION;

ACROMEGALY; ADOLESCENT; ADULT; AGED; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HORMONES; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PEPTIDES, CYCLIC; PITUITARY IRRADIATION; RANDOM ALLOCATION; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 0033739544     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2000.01134.x     Document Type: Article

References (22)

1. Epidemiology of acromegaly in the Newcastle region
2. Epidemiology and long-term survival in acromegaly
3. Binding properties of somatostatin receptor subtypes
4. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide
5. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly
6. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly
7. Long-term therapy with long-acting octreotide (Sandostatin® LAR®) for the management of acromegaly
8. Acromegaly: An epidemiological study
9. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six-month report on an Italian multicenter study
10. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analogue BIM 23014 in patients with acromegaly
11. Relative potencies of the somatostatin analogues octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells
12. Sandostatin LAR in Acromegalic patients: Long term treatment
13. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995
14. Sandostatin® LAR®: A promising therapeutic tool in the management of acromegalic patients
15. Sandostatin LAR: Pharmacokinetics, pharmacodynamics, efficacy and tolerability in acromegalic patients
16. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide
17. Octreotide as primary therapy for acromegaly
18. Long-acting and selective supression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly
19. Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: Evidence for different tumor subclasses
20. Ascertainment and natural history of treated acromegaly in Northern Ireland
21. A comparison of lanreotide and octreotide LAR for treatment of acromegaly
22. Long-term treatment of 189 acromegalic patients with the somatostatin analogue octreotide